Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)

二甲双胍 医学 安慰剂 常染色体显性多囊肾病 肾功能 耐受性 多囊肾病 泌尿科 内科学 不利影响 肾脏疾病 病理 替代医学 胰岛素
作者
Ronald D. Perrone,Kaleab Z. Abebe,Terry Watnick,Andrew D. Althouse,Kenneth R. Hallows,Christina M. Lalama,Dana C. Miskulin,Stephen L. Seliger,Cheng Tao,Peter C. Harris,Kyongtae T. Bae
出处
期刊:Kidney International [Elsevier BV]
卷期号:100 (3): 684-696 被引量:47
标识
DOI:10.1016/j.kint.2021.06.013
摘要

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by growth of kidney cysts and glomerular filtration rate (GFR) decline. Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally considered safe and may be a promising candidate for clinical investigation in ADPKD. In this phase 2 two-year trial, we randomly assigned 97 patients, 18-60 years of age, with ADPKD and estimated GFR over 50 ml/min/1.73 m2, in a 1:1 ratio to receive metformin or placebo twice daily. Primary outcomes were medication safety and tolerability. Secondary outcomes included estimated GFR decline, and total kidney volume growth. Thirty-eight metformin and 39 placebo participants still received study product at 24-months. Twenty-one participants in the metformin arm reduced drug dose due to inability to tolerate, compared with 14 in the placebo arm (not significant). Proportions of participants experiencing serious adverse events was similar between the groups. The Gastrointestinal Symptoms Rating Scale score was low at baseline and did not significantly change over time. The annual change for estimated GFR was -1.71 with metformin and -3.07 ml/min/1.73m2 per year with placebo (mean difference 1.37 {-0.70, 3.44} ml/min/1.73m2), while mean annual percent change in height-adjusted total kidney volume was 3.87% in metformin and 2.16% per year in placebo, (mean difference 1.68% {-2.11, 5.62}). Thus, metformin in adults with ADPKD was found to be safe and tolerable while slightly reducing estimated GFR decline but not to a significant degree. Hence, evaluation of efficacy requires a larger trial, with sufficient power to detect differences in endpoints.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小猪完成签到,获得积分10
1秒前
3秒前
萌面大侠完成签到,获得积分10
3秒前
3秒前
金枪鱼完成签到,获得积分10
4秒前
sssssssssss完成签到,获得积分10
4秒前
mary发布了新的文献求助10
6秒前
研友_VZG7GZ应助hahaha123213123采纳,获得10
6秒前
枕星发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
求求大家了完成签到,获得积分10
9秒前
阳光完成签到,获得积分10
9秒前
Crystal完成签到 ,获得积分10
11秒前
12秒前
12秒前
13秒前
13秒前
13秒前
乐乐应助赖道之采纳,获得10
14秒前
14秒前
Sun_Chen完成签到,获得积分10
14秒前
体贴凌柏发布了新的文献求助10
15秒前
成就的笑南完成签到 ,获得积分10
15秒前
16秒前
16秒前
wyw123完成签到,获得积分10
16秒前
求大佬帮助完成签到,获得积分10
16秒前
李健的小迷弟应助zyq采纳,获得10
17秒前
陈隆完成签到,获得积分10
17秒前
哎呀完成签到 ,获得积分10
17秒前
量子星尘发布了新的文献求助10
18秒前
mary完成签到,获得积分10
18秒前
18秒前
朱成豪发布了新的文献求助10
20秒前
deallyxyz应助科研通管家采纳,获得10
20秒前
科目三应助科研通管家采纳,获得10
20秒前
大个应助科研通管家采纳,获得10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029